Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention
10.3760/cma.j.issn.0253-3758.2011.07.003
- VernacularTitle:细胞色素P4502C19基因多态性对介入术后服用氯吡格雷冠心病患者临床预后的影响
- Author:
Xiao-Fang TANG
1
;
Chen HE
;
Jin-Qing YUAN
;
Xian-Min MENG
;
Yue-Jin YANG
;
Xue-Wen QIN
;
Shu-Bin QIAO
;
Hai-Bo LIU
;
Yong-Jian WU
;
Min YAO
;
Jue CHEN
;
Shi-Jie YOU
;
Yuan WU
;
Jian-Jun LI
;
Jun DAI
;
Ji-Lin CHEN
;
Run-Lin GAO
;
Zai-Jia CHEN
Author Information
1. 北京协和医学院,中国医学科学院,阜外心血管病医院
- Keywords:
Coronary disease;
Cytochrome P-450 enzyme system;
Polymorphism,single nucleotide;
Platelet aggregation inhibitors
- From:
Chinese Journal of Cardiology
2011;39(7):617-620
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impact of cytochrome P450 (CYP) 2C19 681G>A polymorphism on long-term prognosis of clopidogrel-treated Chinese patients after percutaneous coronary intervention (PCI).Methods Between January 1, 2009 and August 31,2009, 267 patients with coronary heart disease who received PCI and treated with clopidogrel for 12 months were enrolled. CYP2C19*2 was detected by MALDI-TOF MS and patients were grouped into CYP2C19*1/*1(n=130) and CYP2C19*2 carriers group (n=137). Follow-up was 12 months. The primary endpoint was angina recurrence, urgent coronary revascularization, acute myocardial infarction, stent thrombosis, death and the combined end points. Results Baseline data were similar between two groups (P>0.05).Urgent coronary revascularization and the combined end points occurred more frequently in CYP2C19*2 carriers than in CYP2C19*1/*1 patients (7.3% vs. 1.5% and 8.0% vs. 2.3% respectively,all P<0.05). But incidence of angina recurrence, acute myocardial infarction, stent thrombosis and death was similar between two groups (all P>0.05).Hazard risk of 1 year cumulative survival of CYP2C19*2 carriers group was significantly higher than CYP2C19*1/*1 group after PCI (HR=3.59, 95%CI: 1.02-12.87, P<0.05). Conclusion CYP2C19 681G>A polymorphism is a determinant of prognosis in coronary heart disease patients receiving chronic clopidogrel treatment after PCI.
